SCHEMBL4154430

SCHEMBL4154430

O=C(O)CNC(=O)c1c(O)c2ccsc2[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
RXFP1 Q9HBX9 1/20 0.45
PARP15 Q460N3 2/20 0.45
TNKS2 Q9H2K2 2/20 0.45
PARP10 Q53GL7 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
TNKS O95271 1/20 0.43
PARP1 P09874 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
KDM5A P29375 1/20 0.40
USP2 O75604 1/20 0.39
HIF1A Q16665 2/20 0.37
BBOX1 O75936 1/20 0.37
ASPH Q12797 1/20 0.37
KDM8 Q8N371 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4155293 0.80 EGLN1 (0.57) EGLN1MEN1KMT2ARXFP1PARP1
SCHEMBL5107518 0.79 SLC22A12 (0.53) MEN1KMT2ARXFP1PARP15TNKS2
SCHEMBL821620 0.76 KMT2A (0.76) MEN1KMT2ARXFP1KDM4ENPC1
SCHEMBL8808303 0.74 XDH (0.55) MEN1KMT2APARP15TNKS2PARP10
SCHEMBL5312360 0.74 GSK3B (0.57) EGLN1MEN1KMT2ARXFP1KDM4E
SCHEMBL5308223 0.74 MEN1 (0.52) EGLN1MEN1KMT2ARXFP1PARP1
SCHEMBL4144587 0.74 EGLN1 (0.40) EGLN1MEN1KMT2ARXFP1KDM4E
SCHEMBL5311454 0.74 MEN1 (0.54) MEN1KMT2ARXFP1KDM4ENPC1
SCHEMBL5107516 0.73 NPC1 (0.63) MEN1KMT2ARXFP1PARP15TNKS2
SCHEMBL822253 0.73 FTO (0.50) EGLN1MEN1KMT2ARXFP1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US claimed
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US disclosed
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US disclosed
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US disclosed
WO-2007136990-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN1 6/4885MEN1 3087/4885KMT2A 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.